{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:38:34Z","timestamp":1793320714612,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on the World Health Organization (WHO)-recommended first-line treatment for &gt;6 months with a plasma viral load &gt;1000 copies\/mL were enrolled and randomly assigned (1:1) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or the WHO-recommended second-line treatment (NRTI group). The primary endpoint was the proportion of patients with a plasma viral load below 50 copies\/mL at 48 weeks. Non-inferiority was prespecified with a margin of 12%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At the time of analysis, week 24 data were available for 83 and 92 patients, and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups, respectively. At 48 weeks, 80.4% of patients in the ABT group and 66.0% of those in the NRTI group had HIV-1 RNA levels below 50 copies\/mL, meeting the criteria for non-inferiority. For the per-protocol population, the superiority of albuvirtide over NRTI was demonstrated. The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration. Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT02369965; https:\/\/www.clinicaltrials.gov.<\/jats:p>\n                    <jats:p>Chinese Clinical Trial Registry No. ChiCTR-TRC-14004276; http:\/\/www.chictr.org.cn\/enindex.aspx<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001273","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T18:00:47Z","timestamp":1606672847000},"page":"2919-2927","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study"],"prefix":"10.1097","volume":"133","author":[{"given":"Bin","family":"Su","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yao","sequence":"additional","affiliation":[{"name":"Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Xia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ping","family":"Cai","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of HIV\/AIDS, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Zhou","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Huang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hua","family":"Li","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang 310023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhu","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Tao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hui","family":"Lun","sequence":"additional","affiliation":[{"name":"Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xia","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jun","family":"Sun","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Dai","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Yi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Xia","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Shan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Peng","sequence":"additional","affiliation":[{"name":"Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Jian","family":"Lu","sequence":"additional","affiliation":[{"name":"Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Hu","sequence":"additional","affiliation":[{"name":"Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xing","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Shao","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xie","sequence":"additional","affiliation":[{"name":"Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,20]]},"reference":[{"key":"R1-20231219","first-page":"1","article-title":"Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2018)","volume":"57","year":"2018","journal-title":"Chin J Intern Med"},{"key":"R3-20231219","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-156-11-201206050-00419","article-title":"Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel","volume":"156","author":"Thompson","year":"2012","journal-title":"Ann Intern Med"},{"key":"R7-20231219","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel","volume":"316","author":"Gunthard","year":"2016","journal-title":"JAMA"},{"key":"R10-20231219","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1016\/S2352-3018(19)30189-4","article-title":"Advanced HIV: diagnosis, treatment, and prevention","volume":"6","author":"Prabhu","year":"2019","journal-title":"Lancet HIV"},{"key":"R12-20231219","first-page":"1075","article-title":"Update on the AIDS\/STD epidemic in China the third quarter of 2018","volume":"24","year":"2018","journal-title":"Chin J AIDS STD"},{"key":"R13-20231219","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/s41598-018-21791-2","article-title":"Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"key":"R14-20231219","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(11)70097-4","article-title":"Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study","volume":"11","author":"Zhang","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R15-20231219","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1097\/01.aids.0000304710.10036.2b","article-title":"The Chinese free antiretroviral treatment program: challenges and responses","volume":"21 Suppl 8","author":"Zhang","year":"2007","journal-title":"AIDS"},{"key":"R16-20231219","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.cr.7290362","article-title":"Current progress of China's free ART program","volume":"15","author":"Zhang","year":"2005","journal-title":"Cell Res"},{"key":"R17-20231219","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fphar.2019.01472","article-title":"Efficacy and tolerability of lopinavir\/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China","volume":"10","author":"Su","year":"2019","journal-title":"Front Pharmacol"},{"key":"R18-20231219","first-page":"385","article-title":"Third Edition of the Guidelines for Diagnosis and Treatment of HIV\/AIDS","volume":"5","year":"2015","journal-title":"Chinese Journal of Clinical Infectious Diseases"},{"key":"R19-20231219","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/CM9.0000000000000647","article-title":"Human immunodeficiency virus prevention strategies in China","volume":"133","author":"Wu","year":"2020","journal-title":"Chin Med J"},{"key":"R20-20231219","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.2634931100","article-title":"Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-20231219","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","article-title":"HIV entry and its inhibition","volume":"93","author":"Chan","year":"1998","journal-title":"Cell"},{"key":"R22-20231219","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2174\/1568026615666150901114527","article-title":"Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41","volume":"16","author":"Lu","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"R23-20231219","doi-asserted-by":"crossref","first-page":"15613","DOI":"10.1073\/pnas.95.26.15613","article-title":"Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target","volume":"95","author":"Chan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-20231219","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/AAC.00976-09","article-title":"An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life","volume":"54","author":"Xie","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20231219","doi-asserted-by":"crossref","first-page":"e32599","DOI":"10.1371\/journal.pone.0032599","article-title":"Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor","volume":"7","author":"Chong","year":"2012","journal-title":"PLoS One"},{"key":"R26-20231219","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"R27-20231219","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"R28-20231219","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"HIV-1 inhibition by a peptide","volume":"365","author":"Jiang","year":"1993","journal-title":"Nature"},{"key":"R29-20231219","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","article-title":"Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients","volume":"13","author":"Zhang","year":"2016","journal-title":"AIDS Res Ther"},{"key":"R31-20231219","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/00498254.2016.1166532","article-title":"Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir\/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results","volume":"47","author":"Yang","year":"2017","journal-title":"Xenobiotica"},{"key":"R32-20231219","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003088-200544020-00003","article-title":"Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide","volume":"44","author":"Patel","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R33-20231219","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1172\/JCI67399","article-title":"Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance","volume":"123","author":"Rabi","year":"2013","journal-title":"J Clin Invest"},{"key":"R34-20231219","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/00365548.2011.552520","article-title":"Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy","volume":"43","author":"Charpentier","year":"2011","journal-title":"Scand J Infect Dis"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:08:02Z","timestamp":1702984082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":26,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001273","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]}}}